Physician profile
Michael Gary
NPI 1851824270
$6,180.40
in general payments reported to CMS, 2019-2025
31 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $150 · 2021: $826 · 2022: $1,266 · 2023: $984 · 2024: $1,195 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,803.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $718.14 | 2019-2025 | |
| Abiomed | $717.07 | 2022-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $467.09 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.61 | 2021-2024 | Jardiance |
| Pfizer INC. | $380.59 | 2020-2025 | |
| Medtronic, INC. | $378.33 | 2021-2025 | Linq II, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $336.82 | 2021-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $322.80 | 2021-2023 | Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $251.24 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $216.31 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $216.16 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Patientcare Link |
| Merck Sharp & Dohme LLC | $198.42 | 2022-2025 | Verquvo |
| Philips North America LLC | $157.58 | 2024-2025 | (6571) Eagle Eye, (Cm9) Amb Mon & Diag Und, Lm Undivided |
| Cvrx, INC. | $145.58 | 2024 | Barostim Neo System |
| Abbott Laboratories | $141.75 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $132.41 | 2025 | Inspire |
| Inari Medical, INC. | $121.42 | 2022 | |
| Lantheus Medical Imaging, INC. | $119.59 | 2019 | |
| Amgen INC. | $117.82 | 2020-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $102.60 | 2025 | Amvuttra |
| Novo Nordisk INC | $97.95 | 2024-2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $97.88 | 2022-2023 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $97.19 | 2022-2025 | |
| Heartflow, INC. | $52.24 | 2025 | |
| Esperion Therapeutics, INC. | $51.84 | 2024-2025 | Nexletol |
| Livanova USA, INC. | $42.67 | 2022 | |
| Impulse Dynamics (USA) INC. | $40.41 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $21.26 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $18.75 | 2025 | Assure Wcd |
| Cardiovascular Systems INC. | $15.08 | 2021 | |
| Scpharmaceuticals INC. | $13.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.